MLI

This form reflects the sale of shares which may be deemed to be beneficially owned by the Reporting Person. The sale was effected pursuant to a previously disclosed Rule 10b5-1 trading plan.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.00 to $138.135, inclusive.

Gift to a donor-advised fund

Gift to a donor-advised fund

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.49 to $108.815, inclusive.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.65 to $104.13, inclusive.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.86 to $105.06, inclusive.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.88 to $105.00, inclusive.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.59 to $104.86, inclusive.

This form reflects the sale of shares which may be deemed to be beneficially owned by the Reporting Person. The sale was effected pursuant to a previously disclosed Rule 10b5-1 trading plan.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.24 to $96.54, inclusive.

9/14/2020

Represents performance-based restricted stock, which may be earned between 0% and 200% of the target amount reported herein based upon the Issuer's actual performance as compared with an adjusted EBITDA target during the three-year period from December 29, 2024 through December 25, 2027. The vesting date is July 30, 2028.

Represents performance-based restricted stock, which may be earned between 0% and 200% of the target amount reported herein based upon the Issuer's actual performance as compared with an adjusted EBITDA target during the three-year period from December 29, 2024 through December 25, 2027. The vesting date is July 30, 2028.

Represents performance-based restricted stock, which may be earned between 0% and 200% of the target amount reported herein based upon the Issuer's actual performance as compared with an adjusted EBITDA target during the three-year period from December 29, 2024 through December 25, 2027. The vesting date is July 30, 2030.

These shares will vest on 7/30/2025.

These shares will vest on 7/30/2025.

These shares will vest on 7/30/2025.

These shares will vest on 7/30/2025.

This form reflects the sale of shares which may be deemed to be beneficially owned by the Reporting Person. The sale was effected pursuant to a previously disclosed Rule 10b5-1 trading plan.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.50 to $82.76, inclusive.

This form reflects the sale of shares which may be deemed to be beneficially owned by the Reporting Person. The sale was effected pursuant to a previously disclosed Rule 10b5-1 trading plan.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.50 to $82.51, inclusive.

This form reflects the sale of shares which may be deemed to be beneficially owned by the Reporting Person. The sale was effected pursuant to a previously disclosed Rule 10b5-1 trading plan.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.50 to $78.57, inclusive.